- Conditions
- Narcolepsy
- Interventions
- JNJ-17216498, Modafinil
- Drug
- Lead sponsor
- Alza Corporation, DE, USA
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 95
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
- Interventions
- Pitolisant
- Drug
- Lead sponsor
- Harmony Biosciences Management, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more
- Conditions
- Narcolepsy
- Interventions
- E2086, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 17
- States / cities
- Santa Ana, California • Brandon, Florida • Medley, Florida + 12 more
- Conditions
- Narcolepsy With Cataplexy, Narcolepsy, Narcolepsy Without Cataplexy
- Interventions
- Mazindol
- Drug
- Lead sponsor
- NLS Pharmaceutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
- Interventions
- Driving Decision Aid, Older Drivers Website
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
- Conditions
- Narcolepsy Type 1
- Interventions
- ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Miami, Florida • Winter Park, Florida • Atlanta, Georgia + 7 more
- Conditions
- Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
- Interventions
- ORX750
- Drug
- Lead sponsor
- Centessa Pharmaceuticals (UK) Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 19
- States / cities
- Auburn, Alabama • Santa Ana, California • Miami, Florida + 14 more
- Conditions
- Narcolepsy Type 1
- Interventions
- TAK-360, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Redwood City, California • Miami, Florida • Cincinnati, Ohio
- Conditions
- Idiopathic Hypersomnia, Narcolepsy
- Interventions
- JZP258 (XYWAV)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 25 more
- Conditions
- Narcolepsy With or Without Cataplexy
- Interventions
- APD916
- Drug
- Lead sponsor
- Arena Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Narcolepsy
- Interventions
- Transition from Xyrem to Xywav
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- ADHD, Narcolepsy
- Interventions
- ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo
- Drug
- Lead sponsor
- Vallon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
- Interventions
- TAK-994, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 36
- States / cities
- Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 31 more
- Conditions
- Excessive Daytime Sleepiness, Narcolepsy
- Interventions
- Placebo, PF-03654746
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
- Conditions
- Narcolepsy, Idiopathic Hypersomnia
- Interventions
- Cognitive-Behavior Therapy for Hypersomnia (CBT-H)
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Narcolepsy, Narcolepsy Type 1, Narcolepsy With Cataplexy, Narcolepsy Type 2, Narcolepsy Without Cataplexy
- Interventions
- Imagery rehearsal therapy, Targeted dream control
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Narcolepsy, Idiopathic Hypersomnia
- Interventions
- 24-hour Ambulatory Blood Pressure Monitoring, Oculo-Cognitive Addition Test (OCAT)
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
- Interventions
- Modafinil, Amphetamine-Dextroamphetamine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Narcolepsy With Cataplexy
- Interventions
- JZP-258, Placebo
- Drug · Other
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 12
- States / cities
- Orange, California • Stanford, California • Boulder, Colorado + 9 more
- Conditions
- Narcolepsy
- Interventions
- JZP-110, Placebo oral tablet
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
- Interventions
- AXS-12 (reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
- Conditions
- Narcolepsy
- Interventions
- Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more
- Conditions
- Narcolepsy, Obstructive Sleep Apnea
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
- Interventions
- CEP-10953 (Armodafinil)
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 41
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more